Interestingly, in the group of WT K-ras tumors (n = 20), there is a trend for a higher OR and a prolonged PFS in patients with CD56 positive tumor as compared with CD56 negative tumor patients and the whole group (CD56+ and CD56- ) (additional file 3, Supplemental Table S2). The gene discussed is NCAM1; the disease is neoplasm.